Vantage logo

Myovant socks it to Orilissa

Two years after Abbvie’s disappointing launch of Orilissa Myovant hails the development of something much better.

Vantage logo

Horizon looks for a new growth driver

The company plans to make the most of its head start with the Graves’ disease project teprotumumab, which is forecast to become its biggest product.